Fibronostics

Mitigating risk by detecting undiagnosed disease through non-invasive, algorithm-based diagnostics.

[Fibronostics @fibronostics]

A recent study shows that patients with severe COVID-19 are at higher risk of liver dysfunction.
#COVID19 #Liver #undiagnosed

https://t.co/sosUxzGCJs

[AASLD @AASLDtweets]

AASLD has created "Clinical Insights for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic"

It provides data on #COVID19, & how it may affect hepatologists & liver transplant providers & their patients.

Read it: https://t.co/J2dj8Dr9ur #LiverTwitter #LTx

[Fibronostics @fibronostics]

Take a look at the papers and oral presentations presented at the NASH-TAG Conference. @NashTagConf #nash

[NASH-TAG Conference @NashTagConf]

🆕 Free papers (orals or posters) and selected oral presentations presented at NASH-TAG can now be cited! Learn more: https://t.co/6SzwUQsNm0 #nash

[NASH-TAG Conference @NashTagConf]

🌎 #Liver History: "The first acknowledged case of obesity-related non-alcoholic fatty liver was observed in 1952 by Samuel Zelman." — @JAMAInternalMed #NAFLD #NASH

[Fibronostics @fibronostics]

Read the latest from @HEP_Journal "Genetic pathways in nonalcoholic fatty liver disease: Insights from systems biology"

[AASLD @AASLDtweets]

From @HEP_Journal: "Genetic pathways in nonalcoholic fatty liver disease: Insights from systems biology" https://t.co/xzI0X3zolS #AASLDjournals #NAFLD

[Fibronostics @fibronostics]

Take a look at abstracts from @NashTagConf past conferences.

[NASH-TAG Conference @NashTagConf]

Review these #NASH abstract books from 2017 - 2020! ⛰️ https://t.co/8FV8tpZzAR

[Fibronostics @fibronostics]

According to the United Nations data, less than 30% of scientific researchers worldwide are women.
https://t.co/FeB16WVQlK #IWD2020 #InternationalWomensDay

[AASLD @AASLDtweets]

From @CLD_Learning: "60 Days in Biliary Atresia: A Historical Dogma Challenged" https://t.co/TaXJUcg6FD #AASLDjournals #BA #LiverTwitter

[Fibronostics @fibronostics]

It is estimated that obesity is linked to more than 60 chronic diseases. #obesity #WorldObesityDay

[World Health Organization (WHO) @WHO]

Today is #WorldObesityDay.
Worldwide obesity has nearly tripled since 1975.
Most of the 🌎🌍🌏's population live in countries where overweight & obesity kills more people than underweight.
Obesity is PREVENTABLE and TREATABLE.
https://t.co/oeuauqWru6

[Fibronostics @fibronostics]

In a recent study, researchers find an alarming increase of #NAFLD in young adults. #liverdisease #fattyliver

https://t.co/nManlFNdeo

[Fibronostics @fibronostics]

#NAFLD, the most common form of chronic liver disease, affects between 30% and 40% of adults in the U.S. #liverdisease
https://t.co/m24OXpNynu

[Fibronostics @fibronostics]

The results of a recent study report adults aged 25 to 34 experienced the highest average annual increase in cirrhosis-related deaths of any age group from 2009 to 2016. #liverdisease #cirrhosis

[AASLD @AASLDtweets]

From @USNewsHealth: "Alcohol Is Growing as a Prime-Time Killer" https://t.co/1kDcyGrkKn @ebtapper @MichiganLiver @NIAAAnews @UnhealthyAlcDrg @GabrielSchnick1 #cirrhosis #LiverTwitter

[Fibronostics @fibronostics]

Researchers discover mobile stroke units offer patients care a half-hour faster than when patients are transported to a hospital by a traditional ambulance. #stroke https://t.co/TjMwxgvNbK

[Fibronostics @fibronostics]

Researchers estimate 1 in 3 adults in the U.K. have early-stage #NAFLD. #liverdisease https://t.co/jkw8AfMFiK

[Fibronostics @fibronostics]

Doctors are reporting an increase of patients who are in their 20's and 30's with symptoms of acute liver disease. #liverdisease

[Mellonpost @mellonpost]

Alcoholic liver disease rates soar among younger people - https://t.co/JEObLty3ES

[Fibronostics @fibronostics]

Researchers test the efficacy of nor-urso in the treatment of #NAFLD. https://t.co/9SL7kfYucn #fattyliver #liverdisease

[Henry E. Chang @HenryEChang]

Prof Brent Neuschwander-Tetri provides a comprehensive overview of the therapeutic landscape for #NAFLD #NASH in 2020 with a focus on drugs in advanced clinical development→https://t.co/xK9y1qj9bk @AGA_Gastro @AmerGastroAssn

[Fibronostics @fibronostics]

A recent study reports participants who consume low levels of sulphur amino acids (15kg-24kg a day) have significantly lower levels of cholesterol, glucose and insulin – and lower overall risk of cardiometabolic diseases.

[The Conversation @ConversationUK]

People who eat higher amounts of sulphur amino acids – found more commonly in meat – were at increased risk of developing heart disease, stroke, diabetes, and non-alcohol fatty liver disease. https://t.co/losBQ9Ouhv

[Fibronostics @fibronostics]

Take a look at this recent article titled, Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. #nash #nafld

[NASH-TAG Conference @NashTagConf]

🆕 #NASH NEWS 📰 Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. Read more: https://t.co/skVsQRBZEt @nresearchnews #meded

[AASLD @AASLDtweets]

JOIN THE CONVERSATION

There's a great discussion around Alcohol Free Beer taking place in Engage, AASLD's online community. Have something to contribute to the conversation? Check it out 👉 https://t.co/r3FRW9DeFF #MemberBenefit #AlcoholFreeBeer #ALDsig